Notice for Applicants: Please refer to updated versions of the Guidelines for Inclusion of Drug Costs v3.1, Applicant submission template v2. and the Budget Impact Model Template v1.5 when making submissions.
Latest Updates…
The NCPE recommends that peg-IRI + 5FU + LV not be considered for reimbursement*.
The NCPE recommends that brentuximab vedotin be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*
Press Release HAG EUNETHTA21 – Professor Michael Barry, Director of the National Centre for Pharmacoeconomics joins the inaugural Heads of Agency Group.
https://www.ncpe.ie/research/covid-19/
The NCPE recommend that darolutamide (Nubeqa®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.
The NCPE recommends that venetoclax in combination with obinutuzumab be considered for reimbursement.*
The NCPE recommends that risankizumab (Skyrizi®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.
Following NCPE assessment of the Applicant’s submission, cost effectiveness of ruxolitinib (Jakavi®) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement unless cost-effectiveness can be improved relative to existing treatments.